Large health systems are acquiring smaller physician practices at what some consider an alarming rate, leaving fewer independent practices.
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo – Pharmaceutical Technology
TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. Credit: Kinga Krzeminska via Getty Images. Ono Pharmaceutical has secured approval from
February 17, 2025